Regenerative Medical Technology (RMTG) EBITDA Margin (2018 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly EBITDA Margin of 8.71% for Q1 2026, down 119.0% year-over-year from 45.82% in Q1 2025, and up 144.68% quarter-over-quarter from 19.48% in Q4 2025.
Regenerative Medical Technology (RMTG) EBITDA Margin (2018 - 2026) Analysis & Trends
Regenerative Medical Technology's EBITDA Margin history runs 9 years deep, the most recent figure standing at 8.71% for Q1 2026.
- In Q1 2026, EBITDA Margin fell 119.0% year-over-year to 8.71%; the TTM figure through Mar 2026 stood at 12.11% (down 1902.0% YoY), while the FY2025 annual figure was 17.0%, down 1898.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 8.71%, up from 19.48% in the prior quarter.
- The five-year high for EBITDA Margin was 25.19% in Q4 2024, with the low at 433.93% in Q4 2022.
- The 5-year median for EBITDA Margin is 21.95% (2023), against an average of 60.08%.
- Peak annual rise in EBITDA Margin reached 541852 bps in 2022, while the deepest fall reached 23737 bps in 2022.
- Regenerative Medical Technology's EBITDA Margin stood at 433.93% in 2022, then soared by 95 bps to 21.95% in 2023, then surged by 215 bps to 25.19% in 2024, then tumbled by 177 bps to 19.48% in 2025, then soared by 145 bps to 8.71% in 2026.
- Business Quant data shows RMTG's EBITDA Margin at 8.71% in Q1 2026, 19.48% in Q4 2025, and 37.76% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 19.75% |
| 10 | Regenerative Medical Technology | 656,948.41 | -404,499.59 | 1.77 Mn | 11.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.71% |
| Dec 31, 2025 | -19.48% |
| Sep 30, 2025 | -37.76% |
| Jun 30, 2025 | -25.43% |
| Mar 31, 2025 | 9.89% |
| Dec 31, 2024 | 25.19% |
| Sep 30, 2024 | 1.99% |
| Jun 30, 2024 | -26.97% |
| Mar 31, 2024 | -12.86% |
| Dec 31, 2023 | -21.95% |
| Sep 30, 2023 | -11.60% |
| Jun 30, 2023 | -119.23% |
| Mar 31, 2023 | -9.44% |
| Dec 31, 2022 | -433.93% |
| Sep 30, 2022 | -43.97% |
| Jun 30, 2022 | -122.89% |
| Mar 31, 2022 | -181.55% |
| Dec 31, 2021 | -196.56% |
| Sep 30, 2021 | -5,462.49% |
| Jun 30, 2021 | -1,614.00% |